Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

TUMADOR

Financiado

Cerrado

Development of very promising humanized therapeutic mAbs efficiently neutralizin...

Development of very promising humanized therapeutic mAbs efficiently neutralizing a novel immunosuppressive pathway involved in a wide range of cancers Studies have demonstrated the importance of CD73 in the spread of cancer. Overexpressed in numerous cancer types, this enzyme leads to the production of high amounts of extracellular Adenosine, creating an immunosuppressive microe... ver más

28/02/2018

CLB

8M€

Presupuesto del proyecto: 8M€

Líder del proyecto

CENTRE DE LUTTE CONTRE LE CANCER LEON BERARD No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 9 Participantes

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2018-02-28 No tenemos la información de la convocatoria

0% 77% 100%

Características del participante

Este proyecto no cuenta con búsquedas de partenariado abiertas en este momento.

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

9 Participantes

CLB

0.00€ | Lider

AYMING

N.D. | Participante

swiss aeropole SA

N.D. | Participante

IPM

N.D. | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Líder del proyecto

CENTRE DE LUTTE CONTRE LE CANCER LEON BERARD No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 8M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Studies have demonstrated the importance of CD73 in the spread of cancer. Overexpressed in numerous cancer types, this enzyme leads to the production of high amounts of extracellular Adenosine, creating an immunosuppressive microenvironment, and contributing to tumor proliferation and dissemination. Neutralizing its activity represents a highly potent and innovative therapy. Following on the recent success of mAbs targeting immune checkpoint (PD1, CTLA4), TumAdoR aims to discover, characterize and produce humanized anti-hCD73 mAbs that will be assessed for their efficacy and safety in relevant mouse preclinical tumor models. It will result in the development of anti-CD73 drug candidates that will strengthen the immune system, stop cancer cell progression and prevent relapse through restoration of immune memory. TumAdoR aims at paving the way to first-in-human clinical trials of potent mAb candidates, and validating a new cancer immunotherapy, suitable for a wide range of cancers. More precisely, TumAdoR will: •Reinforce knowledge about CD73 role as an immune checkpoint target •Correlate CD73 expression with clinical outcome and validate the tumor patients most likely to benefit from CD73 blockade •Discover and develop mAbs neutralizing hCD73 •Develop relevant preclinical tumor models to validate the in vivo efficacy and safety of anti-CD73 mAbs candidate(s) •Develop and standardize tools to assess CD73 expression, and monitor immune parameters in patients TumAdoR addresses topic 1 by developing antibodies neutralizing CD73, and topic 3 by fighting against immune evasion in tumor host microenvironment. The high-level consortium including 3 SMEs possesses all the scientific and clinical expertises, industrial competences, biological and enzymatic assays, biological and clinical resources, and preclinical models to discover and produce mAbs, and investigate the functions of CD73, and the therapeutic impact of its neutralization.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores